Contingency Management for Smoking Cessation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to help people quit smoking, focusing on those with cancer or suspected cancer who are planning surgery. Half of the participants will receive a novel smoking cessation treatment called Contingency Management (also known as Motivational Incentives or the Prize Method), while all participants will receive standard support, such as counseling and nicotine patches. The researchers aim to determine if this new approach helps more people stop smoking compared to usual methods. Individuals who smoke at least one tobacco product daily and have a cancer diagnosis or suspicion may be suitable for this trial. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance smoking cessation methods for cancer patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that Contingency Management is safe for smoking cessation?
Studies have shown that financial rewards, such as money or vouchers, can help people quit smoking and are generally well-received. Research indicates that these rewards effectively encourage smoking cessation and maintain smoke-free status without major side effects. Previous findings suggest that offering these incentives does not typically lead to harmful effects but instead helps maintain motivation to quit smoking. This method has succeeded in different settings and among various groups, suggesting it is a safe and promising way to support smoking cessation.12345
Why are researchers excited about this trial?
Contingency Management is unique because it uses a behavioral approach to encourage smoking cessation by offering incentives for meeting specific goals, like staying smoke-free. Unlike standard treatments that often rely on medication or counseling alone, this method directly rewards individuals for making positive changes, which can be a powerful motivator. Researchers are excited about this approach because it leverages the natural human response to rewards, potentially making it more effective for some people than traditional methods.
What evidence suggests that this trial's treatments could be effective for smoking cessation?
This trial will compare Contingency Management, which uses financial rewards to encourage quitting, with Standard Care for smoking cessation. Studies have shown that reward-based methods can significantly reduce smoking compared to standard care. However, some studies found that while these methods work well in the short term, the benefits might not last over time. Overall, strong evidence supports using incentives to quit smoking, and it is considered a promising strategy for helping people quit.12678
Who Is on the Research Team?
Benjamin Toll, PhD
Principal Investigator
Medical University of South Carolina
Are You a Good Fit for This Trial?
This trial is for adult smokers diagnosed with or suspected to have operable cancer, who are about to undergo surgery. Participants must smoke at least one cigarette daily and speak English. Those using alternative nicotine products, pregnant women, or individuals with unstable psychiatric/medical conditions cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard smoking cessation therapy including counseling and the nicotine patch. Half of the participants receive a novel smoking cessation treatment.
Follow-up
Participants are monitored for smoking abstinence through self-report, Carbon Monoxide Breath Monitoring, and Anabasine testing.
What Are the Treatments Tested in This Trial?
Interventions
- Contingency Management
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
National Cancer Institute (NCI)
Collaborator